Reference

AMET works diligently to keep the following information updated with the most current medical aesthetic news.  This information has been supplied by numerous sources. AMET is not affiliated with any such sources, and the information provided does not reflect the views of AMET.  The function of this page is to simply provide information, and AMET does not accept responsibility or liability for any views/claims/rumors/errors that appears herein.  

5/6/2014
Reconstitution is key to optimizing neurotoxin results
IncobotulinumtoxinA (Xeomin, Merz) is equivalent to onabotulinumtoxinA (Botox, Allergan) in efficacy and safety, but the former product needs to be reconstituted in a different fashion from onabotulinumtoxin A to achieve equivalent efficacy.

Montreal IncobotulinumtoxinA (Xeomin, Merz) is equivalent to onabotulinumtoxinA (Botox, Allergan) in efficacy and safety, but the former product needs to be reconstituted in a different fashion from onabotulinumtoxin A to achieve equivalent efficacy.
"Although more than 3,000 patients in numerous studies show that both products are comparable, a small number of studies have shown incobotulinumtoxinA to be inferior to onabotulinumtoxinA," said Wayne Carey M.D., F.R.C.P.C., associate professor of dermatology at McGill University, Montreal, speaking at a dermatology symposium here.
"The reason for this inferiority is because the product was most likely mixed the same way that onabotulinumtoxinA was. If you reconstitute incobotulinumtoxinA, the way you would onabotulinumtoxinA, you will have a significant loss of product (incobotulinumtoxin A)," Dr. Carey says.
- See more at: http://dermatologytimes.modernmedicine.com/dermatology-times/news/RC/reconstitution-key-optimizing-neurotoxin-results#sthash.P1IAAZk6.dpuf

http://dermatologytimes.modernmedicine.com/dermato...

back to reference main